High-Dose Prophylactic Gabapentin (HOPE) to Prevent Opioid Use for Oral Mucositis Pain During Head and Neck Chemoradiotherapy: A Phase III Clinical Trial
High-Dose Prophylactic Gabapentin (HOPE) to Prevent Opioid Use for Oral Mucositis Pain During Head and Neck Chemoradiotherapy: A Phase III Clinical Trial
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region
PRIMARY OBJECTIVE:
I. To determine whether prophylactic high dose gabapentin, titrated to a dose of 3600 mg (1200 mg three times per day [TID]), is superior to placebo in increasing the proportion of patients not needing opiates while undergoing chemoradiation therapy.
SECONDARY OBJECTIVES:
I. To determine whether prophylactic high dose gabapentin is superior to placebo in prolonging the time to first opioid use while undergoing chemoradiation therapy.
II. To determine whether prophylactic high dose gabapentin is superior to placebo in improving patient reported pain scores using the 0-10 numerical rating scale (NRS) from baseline to 4 weeks after the end of chemoradiation therapy.
EXPLORATORY OBJECTIVES:
I. To explore the duration of opioid use from the time of initiation to cessation by arm as well as describe the proportion of patients remaining on opioids at 3 months, 6 months, and 1 year by arm.
II. To explore the trajectory of patient reported symptom and quality of life outcomes using the Oral Mucositis Weekly Questionnaire (OMWQ) by arm.
III. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) by arm.
IV. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck-43 (EORTC QLQ-H&N43) by arm.
V. To evaluate the adverse event profiles of prophylactic high dose gabapentin versus placebo.
VI. To assess the tolerance of high dose gabapentin. VII. To explore the trajectory of patient health using patient body mass index (BMI) and creatinine, absolute neutrophil count (ANC) as routinely obtained by arm.
VIII. To describe the incidence of feeding tube requirement during and after chemoradiation therapy by arm.
IX. To describe the dose of prescribed opioids standardized using the Morphine Milligram Equivalent calculator by arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Starting by radiation treatment 8, patients receive placebo orally (PO) once daily (QD) on day 1, twice daily (BID) on day 2, then three times daily (TID) starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.
ARM II: Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 4 weeks, 3 months and 6 months after the last dose of chemoradiation therapy.
Inclusion Criteria:
Histologic documentation of disease: Squamous cell carcinoma of the head and neck region.
* Stage: I-IV
No prior treatment for head and neck cancer
Planned treatment with cisplatin-based chemoradiation therapy (weekly or once every 3 weeks [q 3 week])
Able to swallow capsules whole
No known hypersensitivity to gabapentin or its ingredients
No patients on dialysis or with transplanted organs
No prior surgery or radiation for head and neck cancer and/or are being treated for recurrent head and neck cancer. Patients with a history of surgery and radioactive iodine for the treatment of thyroid cancer are eligible. Concurrent cancer therapy for other cancers is not allowed
No planned surgery or chemotherapy or immunotherapy following 7 weeks of standard chemoradiation treatment
No known brain metastases
No nonprescribed use of any opioids (including heroin) within 6 months prior to registration
No prescribed medications for chronic and/or long-term pain and/or neuropathy, including patients under treatment of a pain specialist or substance abuse programs. Acute post-biopsy medications are allowed if the patient has discontinued them 3 days prior to study registration
No current treatment with mefloquine
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Creatinine ≤ 1.5 x upper limit of normal (ULN)
Not pregnant and not nursing, because this study involves both radiation and chemotherapy. In addition, the genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential, a negative pregnancy test done < 7 days prior to registration is required. Women must agree to using contraception for the duration of receiving study drugs and for 6 months after completing chemoradiation
Not taking medications for a psychotic psychiatric illness
No existing diagnosis of sleep apnea
No acute narrow-angle glaucoma
No uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
No investigational agent within 30 days prior to registration
No enrollment on other studies of systemic pain control agents
Language: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish
Patients with impaired decision making are not eligible for study
Exclusion Criteria:
-
cancercontrolprotocols@alliancenctn.org773-702-9171
Gilbert, Arizona 85297, United States
penny.labriola@arizonaccc.com480-278-8261
Bakersfield, California 93301, United States
San Jose, California 95119, United States
Santa Clara, California 95051, United States
South San Francisco, California 94080, United States
Honolulu, Hawaii 96819, United States
South Portland, Maine 04106, United States
Forest Hills, New York 11375, United States
Harrisburg, Pennsylvania 17109, United States
Mechanicsburg, Pennsylvania 17050, United States
Pittsburgh, Pennsylvania 15232, United States
Wilkes-Barre, Pennsylvania 18711, United States
Sioux Falls, South Dakota 57117-5134, United States
Summit, Wisconsin 53066, United States
ncorp@aurora.org414-302-2304
West Bend, Wisconsin 53095, United States
623-773-2873
penny.labriola@arizonaccc.com480-278-8261
penny.labriola@arizonaccc.com480-278-8261
penny.labriola@arizonaccc.com480-278-8261
penny.labriola@arizonaccc.com480-278-8261
ctsucontact@westat.com888-823-5923
penny.labriola@arizonaccc.com480-278-8261
661-323-4673
uscnorrisinfo@med.usc.edu323-865-0451
323-865-0451
KPCOIHRClinicalResearch@kp.org303-817-9295
KPCOIHRClinicalResearch@kp.org303-817-9295
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
eslinget@slhs.org208-381-2774
mccinfo@mtcancer.org406-969-6060
eslinget@slhs.org208-381-2774
eslinget@slhs.org208-381-2774
eslinget@slhs.org208-381-2774
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
ncorp@aah.org
847-842-4847
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
773-296-5360
advocateresearch@advocate.com630-929-6129
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
815-285-7800
Barbara.barhamand@advocatehealth.com630-275-1270
morganthaler.jodi@mhsil.com217-876-4762
847-429-2907
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
708-799-9995
andersonj@illinoiscancercare.com309-243-3605
advocateresearch@advocatehealth.com630-929-6129
advocateresearch@advocatehealth.com630-929-6129
andersonj@illinoiscancercare.com309-243-3605
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
800-323-8622
ncorp@aah.org
andersonj@illinoiscancercare.com309-243-3605
ncorp@aah.org
847-384-3621
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
217-545-7929
800-444-7541
pallante.beth@mhsil.com217-528-7541
andersonj@illinoiscancercare.com309-243-3605
515-956-4132
ksoder@mcfarlandclinic.com515-239-4734
Rachel.varner@unitypoint.org319-368-5514
319-365-4673
319-363-2690
515-956-4132
515-956-4132
207-626-4855
protocols@AllianceNCTN.org773-702-9171
clinicalresearch@mainehealth.org207-396-8670
clinicalresearch@mainehealth.org207-396-8670
clinicalresearch@mainehealth.org207-396-8670
207-459-1600
clinicalresearch@mainehealth.org207-396-8670
clinicalresearch@mainehealth.org207-396-8670
OncologyClinicalTrialsFargo@sanfordhealth.org218-333-5000
coborncancercenter@centracare.com877-229-4907
sfmc@sfmc.net573-334-2230
LJCrockett@freemanhealth.com417-347-4030
Danielle.Werle@mercy.net314-525-6042
314-251-7066
mccinfo@mtcancer.org406-969-6060
research@billingsclinic.org800-996-2663
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
unmcrsa@unmc.edu402-559-6941
402-354-5144
402-559-5600
unmcrsa@unmc.edu402-559-6941
ONCTrialNow@jefferson.edu215-600-9151
ONCTrialNow@jefferson.edu215-600-9151
askroswell@roswellpark.org800-767-9355
718-520-6620
516-734-8896
212-434-4460
516-734-8896
718-312-3446
800-862-2215
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org701-234-6161
ClinicalReserachDept@aultman.com330-363-7274
ou-clinical-trials@ouhsc.edu405-271-8777
HemonCCTrials@geisinger.edu570-271-5251
hemoncctrials@geisinger.edu877-204-6081
ClinicalResearchServices@upmc.edu412-864-7716
814-452-5000
protocols@AllianceNCTN.org773-702-9171
724-838-1900
klitchfield@PINNACLEHEALTH.org717-724-6765
ddefazio@wpahs.org412-359-3043
HemonCCTrials@geisinger.edu570-374-8555
haneydl@upmc.edu412-389-5208
412-858-7746
protocols@AllianceNCTN.org773-702-9171
ClinicalResearchServices@upmc.edu412-864-7716
ONCTrialNow@jefferson.edu215-600-9151
ONCTrialNow@jefferson.edu215-600-9151
877-284-2000
412-647-8073
412-621-2334
412-502-3920
HemonCCTrials@geisinger.edu800-275-6401
814-676-7900
Dawnmarie.DeFazio@ahn.org
HemonCCTrials@geisinger.edu570-271-5251
ONCTrialNow@jefferson.edu215-600-9151
kmertz-rivera@gibbscc.org864-560-6104
kmertz-rivera@gibbscc.org864-560-6104
OncologyClinicTrialsSF@sanfordhealth.org605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org605-312-3320
cancerinfo@hci.utah.edu888-424-2100
cancerinfo@hci.utah.edu888-424-2100
cancerinfo@hci.utah.edu888-424-2100
cancerinfo@hci.utah.edu888-424-2100
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
304-487-7515
304-243-6442
Juli.Alford@aspirus.org715-623-9869
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
cancerctr@gundersenhealth.org608-775-2385
ncorp@aurora.org414-302-2304
Beth.Knetter@aspirus.org715-847-2353
262-257-5100
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
414-805-3666
ncorp@aurora.org414-302-2304
414-805-0505
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
Beth.Knetter@aspirus.org715-847-2353
ncorp@aurora.org414-302-2304
Beth.Knetter@aspirus.org715-847-2353
ncorp@aurora.org414-302-2304
877-405-6866
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
414-805-0505
715-422-7718